Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
Kenneth C. Griffin, founder and CEO of Citadel and founder of Griffin Catalyst, gifted $50 million to Sylvester Comprehensive Cancer Center to help fund a 12-story, 244,000-square-foot cancer research building.
Damian Green will join Sylvester Comprehensive Cancer Center at the University Miami Miller School of Medicine this spring to lead its transplantation and cellular therapy services. Green was named chief of the Division of Transplantation & Cellular Therapy, as well as assistant director of Translational Research, beginning March 1.
A study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into glioblastoma neuron mimicry and potential therapies to prevent treatment resistance.